General Hospital of Benxi Iron and Steel CO., LTD. Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2019
NCT03955367
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

General Hospital of Benxi Iron and Steel CO., LTD. | General Hospital of Benxi Iron & Steel Industry Group

Active Ingredients

Drugs in Phase 3 Trials (2)

docetaxel (taxotere) (1 trial)

nedaplatin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2